Jupiter Neurosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $9.3M
- Price
- $0.1911
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.88%
- Volume
- 3.2M
Quote data as of 5:25 AM ET
About
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
Quick stats
Shares outstanding48.2M
Computed float7.4M
Float sourceUnknown
Cash runway (months)1
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001679628
AI Summary
AI-generated1mo agostandardbullishclinical trialJupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
Jupiter Neurosciences has begun patient enrollment in its Phase 2a RESET trial for JOTROL, an investigational oral therapy for Parkinson’s Disease.
The multi-center, randomized, double-blind, placebo-controlled study aims to enroll 30 patients across three sites in the Washington D.C. area, with a 12-week duration and projected completion in the first half of 2027.
Primary endpoints focus on safety, tolerability, and pharmacokinetics, building on Phase 1 data that showed JOTROL achieves approximately 9-fold higher plasma bioavailability than conventional resveratrol with no serious adverse events.
Red flags
- Small Phase 2a cohort (n=30) limits statistical power for efficacy signals
- Proposed acquisition of ALA-002 from PharmAla Biotech remains subject to due diligence and definitive agreements
- No disease-modifying therapies currently approved for PD; high competitive risk